# How Lipfendra, Inclisiran, and New Guidelines Are Changing Cholesterol Management
New medications and updated clinical guidelines are reshaping how doctors treat high cholesterol, offering parents and patients additional options beyond traditional statins.
Lipfendra and Inclisiran represent two distinct approaches to cholesterol control. Lipfendra combines bempedoic acid with lesinurad, targeting uric acid production alongside cholesterol reduction. This dual action makes it useful for patients who also struggle with gout. Inclisiran takes a different route through gene-silencing technology, using small interfering RNA to reduce LDL cholesterol production at the source. Patients receiving Inclisiran need just two initial injections, followed by maintenance doses every six months, simplifying the treatment burden compared to daily pills.
These additions matter because high cholesterol runs in families. Children with familial hypercholesterolemia face elevated heart disease risk from birth, and parents need all available tools to manage their offspring's cholesterol levels early. New clinical guidelines now reflect these options, giving doctors flexibility to personalize treatment plans based on individual patient needs, side effect profiles, and adherence challenges.
The shift toward more treatment choices addresses real problems. Some patients experience statin-related muscle pain or liver complications. Others struggle with daily medication routines. Inclisiran's infrequent dosing schedule appeals to families managing busy lives. Lipfendra works well for patients whose cholesterol and gout both need controlling.
Parents should understand that these medications don't replace lifestyle changes. Diet, exercise, and weight management remain foundational. But for children and adults with genetic predisposition or those who don't respond adequately to standard therapies, Lipfendra and Inclisiran offer new pathways to better heart health.
Discussing these options with your pediatrician or cardiologist